(Q35096843)

English

Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

atrial fibrillation

0 references

author name string

Gerald V Naccarelli

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Deborah L Wolbrette

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mazhar Khan

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Luna Bhatta

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

John Hynes

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Soraya Samii

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jerry Luck

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

6A

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

15D-26D

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Management of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Atrial fibrillation: maintenance of sinus rhythm versus rate control

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

A comparison of rate control and rhythm control in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Electrophysiology and pharmacology of ibutilide

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Verapamil reduces tachycardia-induced electrical remodeling of the atria

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Adverse effects of low dose amiodarone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

New antiarrhythmic drugs for the treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Cardiovascular drugs. Dofetilide

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Dofetilide: a new pure class III antiarrhythmic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Issues in the use of generic antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Adverse effects of amiodarone. Pathogenesis, incidence and management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Controlled trial of sotalol for one year after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

The azimilide post-infarct survival evaluation (ALIVE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Dep

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Outcome studies with device therapy in patients with heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Sex-based differences in the effect of digoxin for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Pathophysiology and prevention of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903375-1

7 January 2021

Identifiers

10.1016/S0002-9149(02)03375-1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35096843&oldid=1638655443"